RESUMO
Intracranial stenting, with or without balloon angioplasty, has emerged as an effective alternative to medical therapy for intracranial atherosclerosis. However, this strategy appears to involve the potential risk of distal embolization, which may lead to disability and death. Here, the authors have described a successful case of distal balloon-protected intracranial carotid artery stenting for clinically and angiographically unstable intracarotid artery stenosis revealing aspirated embolic materials containing yellow plaque, red thrombus, and white debris.
Assuntos
Angioplastia com Balão , Artéria Carótida Interna , Estenose das Carótidas/terapia , Arteriosclerose Intracraniana/terapia , Embolia Intracraniana/etiologia , Ataque Isquêmico Transitório/etiologia , Stents , Idoso , Angioplastia com Balão/efeitos adversos , Angioplastia com Balão/instrumentação , Oclusão com Balão , Artéria Carótida Interna/patologia , Estenose das Carótidas/complicações , Estenose das Carótidas/patologia , Angiografia Cerebral , Imagem de Difusão por Ressonância Magnética , Feminino , Humanos , Arteriosclerose Intracraniana/complicações , Arteriosclerose Intracraniana/patologia , Embolia Intracraniana/complicações , Embolia Intracraniana/patologia , Embolia Intracraniana/prevenção & controle , Ataque Isquêmico Transitório/patologia , Ataque Isquêmico Transitório/prevenção & controle , Inibidores da Agregação Plaquetária/uso terapêutico , Desenho de Prótese , Resultado do TratamentoRESUMO
In vivo efficacy of tosufloxacin (TFLX) for treatment of Chlamydia trachomatis cervical infection in women was evaluated by enzyme immunoassay. The short term (within 31 days of treatment) response rates with a dosage of 150mg orally 3 times daily were 100% (54/54) with 14 days of treatment and 97% (38/39) with 7 days of treatment. Subjective symptoms such as lower abdominal pain, vaginal discharge, or atypical bleeding were observed in 76 (82%) of the 93 patients. After treatment, symptoms improved in 75 (99%) of 76 patients. Two of 34 patients (5.9%) showed positive results in the long interval tests (1 to 18 months after treatment). Three (2.3%) of 131 patients needed to be changed from TFLX to other drugs due to side effects (eczema, face edema, urticaria). TFLX was effective and patients showed high compliance for treatment of cervical C. trachomatis infection.
